Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
This is a brief. The reporting belongs to MarketWatch — read the complete story, with full context and credits, at the source.
Read the full story at MarketWatch ↗marketwatch.com
More from the Business desk
Just in

What to know about the Nvidia turmoil.
Just in